Adenocarcinoma has become the most common histological type of lung cancer, approximately half of lung cancer patients are diagnosed with adenocarcinoma, and the incidence is rapidly increasing worldwide[@b1][@b2]. Metastatic pulmonary adenocarcinomas often manifest as pleural effusion, while some cases present as pericardial, or peritoneal effusions[@b3]. It is important to identify the primary site of adenocarcinomas in pleural, pericardial, and peritoneal effusions, since this information guides disease treatment and management, as well as prognosis assessment[@b4]. However, identifying adenocarcinoma origin can be challenging; for example, it is difficult or even impossible to differentiate metastatic pulmonary adenocarcinomas from non-pulmonary adenocarcinomas on the basis of morphology and effusion samples[@b5]. Positive cytology examination may suggest the presence of malignant diseases, but it may not indicate the primary site of adenocarcinoma.

Immunostaining can help identify the site of origin, but most adenocarcinoma markers are not organ-specific. This highlights the need for more biologically specific markers for pulmonary adenocarcinomas in order to distinguish metastatic pulmonary from non-pulmonary adenocarcinomas in pleural, pericardial, and peritoneal effusions[@b6][@b7]. Thyroid transcription factor 1 (TTF-1) is a homeodomain-containing transcription factor selectively expressed in the thyroid, diencephalon and lung[@b8]. TTF-1 was recently proposed as an immunohistochemical marker of pulmonary adenocarcinomas, with one meta-analysis reporting overall sensitivity of 76% and specificity of 100% in tissue samples[@b9]. TTF-1 also plays a role in the diagnosis of malignant effusion[@b10]. Studies suggest that TTF-1 is a potential biomarker for differentiating pulmonary adenocarcinomas from non-pulmonary adenocarcinomas in pleural or other effusions[@b11][@b12][@b13], but results from these studies have not always been consistent. Therefore we meta-analyzed the available evidence on whether TTF-1 can distinguish metastatic pulmonary adenocarcinomas from non-pulmonary adenocarcinomas in pleural or other effusions.

Material and Methods
====================

This meta-analysis was conducted and reported according to the guidelines of the Preferred Reporting Items for Systematic Reviews, the Meta-analysis Statement and methods recommended by the Cochrane Diagnostic Test Accuracy Working Group[@b14][@b15]. There was no need for institutional review board approval for this retrospective meta-analysis.

Literature search
-----------------

Two investigators (Y. Shen and C. Pang) searched in PubMed, EMBASE, Web of Knowledge, CNKI, WANFANG, and WEIPU databases for relevant articles published up to May 2015. The following search terms were used as Medical Headings and/or text words: "Thyroid transcription factor 1 OR TTF-1" AND "pleural effusion OR pleural fluid OR hydrothorax OR ascites OR peritoneal effusion OR pericardial effusion OR serous effusion" AND "sensitivity OR specificity OR accuracy". Reference lists of the included studies and review articles were also checked to identify additional studies.

Selection of eligible studies
-----------------------------

A study was included if it fulfilled the following criteria: (i) it examined the ability of TTF-1 to differentiate metastatic pulmonary adenocarcinomas from non-pulmonary adenocarcinomas in humans; (ii) it analyzed pleural, pericardial, and peritoneal effusions as samples; (iii) it reported sufficient data to allow calculation of true positive (TP), false positive (FP), false negative (FN), and true negative (TN) rates; (iv) it reported definitive determination of metastatic pulmonary adenocarcinomas and non-pulmonary adenocarcinomas using gold-standard methods; and (v) it was an original research study published in English or Chinese. Conference proceedings and studies published only as abstracts were excluded. To avoid selection bias, we also excluded studies involving fewer than 20 patients. When several articles concerned the same subjects, only results from the publication with the largest sample were used.

Data extraction
---------------

Two reviewers (Y. Shen and C. Pang) independently identified eligible studies and extracted data on study methodology, characteristics and test accuracy using a standardized extraction form. The data extracted were: name of first author, publication year, country, serous effusion types, sample preparation method, TTF-1 immunostaining method, antibody clone and dilution, and two-by-two tables of TP, TN, FP and FN. Detailed information about controls with non-pulmonary adenocarcinoma was also reviewed.

Assessment of methodological quality
------------------------------------

The same two reviewers (Y. Shen and C. Pang) assessed the quality of the selected studies using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) criteria, which cover four key domains for assessing risk of bias and applicability of the study results. These domains are patients selection, index test, reference standard, and flow and timing of samples/patients through the study[@b16]. Any discrepancies between the two authors (Y. Shen and C. Pang) during study selection, data extraction or quality assessment were resolved by discussion with a third author (K. Shen).

Statistical analysis
--------------------

We used standard methods recommended for bivariate meta-analysis of diagnostic test evaluations[@b17]. We descriptively analyzed study characteristics and QUADAS-2 quality assessment using Excel and Review Manager 5.2 (The Cochrane Collaboration, Copenhagen, Denmark). The following measures of test accuracy were computed for each study, together with 95% confidence intervals (95% CIs): sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odds ratio (DOR). A summary ROC (SROC) curve covering all the studies was plotted using the data on sensitivity and specificity for a single test threshold from each study. The area under the SROC curve (AUC) was used to summarize the overall diagnostic performance of TTF-1.

The heterogeneity effect was measured using the Q test and the inconsistency index (I^2^). P \< 0.05 or I^2^ ≥ 50% indicated significant heterogeneity, which was then analyzed through meta-regression to identify potential covariates. Deeks's funnel plot was used to detect publication bias[@b18]. Post-test probability was calculated using the overall prevalence of 20% with Fagan nomograms. All analyses were performed using the "Midas" module in STATA 12.0 (Stata Corp., College Station, TX), and Meta-DiSc 1.4 for Windows (XI, Cochrane Colloquium, Barcelona, Spain). All statistical tests were two-sided, with P \< 0.05 taken as the threshold for statistical significance.

Results
=======

Systematically searching literature databases and manually searching reference lists in relevant reviews and studies identified 20 studies examining the diagnostic accuracy of TTF-1 in pleural or other effusions in patients with metastatic pulmonary adenocarcinomas[@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38]. Studies were excluded because they were not diagnostic studies, they did not report sufficient data to construct 2 × 2 tables, or they mixed other type of cancers like squamous-cell carcinoma. The process of selecting of studies eligible for inclusion is shown in [Fig. 1](#f1){ref-type="fig"}.

Patient characteristics and study design
----------------------------------------

The final set of 20 studies involved 1,213 subjects, comprising 668 patients with metastatic pulmonary adenocarcinomas and 545 controls with non-pulmonary adenocarcinomas (median 60 patients per study; range 32--113 patients). ([Table 1](#t1){ref-type="table"}). Thirteen studies were performed in Asia, six in the USA, and one in Europe. The most frequent cancer types among the 545 patients with non-pulmonary adenocarcinomas were breast (n = 178), gastrointestinal (n = 147) and ovary adenocarcinomas (n = 145). Eight studies assayed pleural effusion; four studies, pleural effusion, pericardial effusion, and ascites; another four studies, pleural effusion and ascites; two studies, only mentioned as serous effusions; one study, pleural effusion and pericardial effusion; and one study, only pericardial effusion. Only two studies involved analysis of smear samples[@b25][@b34]; the remainder relied on analysis of cell blocks. [Table 2](#t2){ref-type="table"} summarizes individual study designs and results for diagnostic performance of TTF-1.

Most studies detected TTF-1 using the 8G7G3/1 antibody; three used the SPT24 antibody[@b33][@b34][@b37], and one study did not report this information[@b35]. Twelve studies used immunohistochemistry to detect TTF-1, while the remaining eight used immunocytochemistry. Antibody dilutions from 1:40 to 1:500 were used in the included studies, while five did not report dilution factors. All studies defined nuclear staining as positive. [Supplemental Table 1](#S1){ref-type="supplementary-material"} summarizes the clinical information of patients with non-pulmonary adenocarcinomas.

Methodological quality of the included studies
----------------------------------------------

QUADAS-2 was proposed in 2011 as an improved redesign of the original QUADAS and it was integrated into RevMan 5.2 in 2012. We applied the four criteria of QUADAS-2 (patient selection, index test, reference standard, flow and timing) to the studies in our meta-analysis. A response of "Yes" was given if the criterion was fulfilled, "Unclear" if fulfillment was unclear, and "No" if the criterion was not fulfilled. Based on these responses, the risk of bias for each criterion was classified as low, high, or unclear. Based on the first three domains, the applicability of the results was also evaluated. The quality of included studies was generally good, but three studies[@b19][@b21][@b27] were at high risk of bias due to deficiencies in patient selection. [Figure 2](#f2){ref-type="fig"} shows the summary of QUADAS-2 assessments of included studies.

Diagnostic accuracy of TTF-1
----------------------------

Sensitivity of TTF-1 for diagnosing metastatic pulmonary adenocarcinomas in effusions was between 0.54 and 0.88, and the pooled sensitivity was 0.74 (95% CI: 0.69--0.79). Specificities of TTF-1 varied from 0.92 to 1.00, and the pooled specificity was 0.99 (95% CI: 0.97--1.00). The other pooled parameters for TTF-1, calculated over all 20 studies, were: PLR, 78.16 (95% CI: 27.15--225.05); NLR, 0.26 (95% CI: 0.22--0.32); and DOR, 297.75 (95% CI: 104.16--851.19) ([Fig. 3](#f3){ref-type="fig"}).

[Figure 4](#f4){ref-type="fig"} shows a plot of the TP rate as a function of the FP rate in individual studies, as well as the corresponding SROC curve. The AUC was 0.96, indicating a high discriminatory ability for TTF-1. Fagan's nomogram for likelihood ratios ([Fig. 5](#f5){ref-type="fig"}) indicated that using TTF-1 to detect metastatic pulmonary adenocarcinomas increased the post-probability to 95% when the results were positive, and reduced the post-probability to 6% when the results were negative.

Meta-regression and publication bias
------------------------------------

I^2^ values for diagnostic performance indices were as follows: sensitivity, 51.7% (P = 0.00); specificity 30.2% (P = 0.10); PLR 0.00% (P = 0.16); NLR, 57.57% (P = 0.00); and DOR, 99.20% (P = 0.00). This suggests high heterogeneity among included studies, so, a meta-regression was performed to identify possible sources of heterogeneity. The meta-regression featured six covariates: (i) country of origin (Asia vs. non-Asia); (ii) TTF-1 assay method (immunohistochemistry vs. immunocytochemistry), (iii) TTF-1 clone (8G7G3/1 vs. other); (iv) TTF-1 antibody dilution (≤1:150 vs. \>1:150 and other), (v) study design (prospective vs. retrospective); and (vi) blinding (blind vs. other). None of these covariates was found to be a significant source of heterogeneity (all P \> 0.05, [Table 3](#t3){ref-type="table"}).

Deeks's funnel plot asymmetry test was used to assess likelihood of publication bias in the included 20 studies. The slope coefficient was associated with P = 0.11, suggesting symmetry in the data and low likelihood of such bias ([Fig. 6](#f6){ref-type="fig"}).

Discussion
==========

Diagnosing lung adenocarcinoma based on resection histology is normally straightforward, but diagnosing metastatic pulmonary adenocarcinomas based on effusion samples can be extremely challenging[@b5][@b6]. Available biomarkers in effusions differentiate poorly between pulmonary adenocarcinomas and non-pulmonary adenocarcinomas. TTF-1 has emerged as a promising candidate biomarker, but studies of its diagnostic performance have given conflicting results[@b11][@b12][@b13]. Our meta-analysis is strengthened by the use of a standard protocol, strict inclusion criteria, standardized data extraction, independent reviewers, and a bivariate random-effects model[@b39]. Our meta-analysis of available evidence suggests that TTF-1 can accurately predict whether an adenocarcinoma cell originated from a pulmonary or non-pulmonary site. However, TTF-1 probably cannot stand on its own and so should be used in conjunction with other markers.

Our meta-analysis indicated that TTF-1 performed with medium sensitivity (0.74, 95% CI: 0.69--0.79); and high specificity (0.99, 95% CI: 0.98--1.00), with a relatively high rate of missed diagnoses (16%) but a low rate of misdiagnosis (1%). These findings suggest that TTF-1 is a highly specific marker of pulmonary adenocarcinoma origin in pleural and other effusions. The SROC curve, which assesses overall test performance by showing the trade-off between sensitivity and specificity[@b40], had an AUC of 0.96, suggesting high overall accuracy. Another indicator of diagnostic accuracy is DOR, which combines sensitivity and specificity data into a single number ranging from 0 to infinity, with higher values indicating better discriminatory test performance. Mean DOR in our meta-analysis was 297.75, suggesting that assaying TTF-1 should be helpful in the diagnosis of metastatic pulmonary adenocarcinomas. We further examined the diagnostic accuracy of TTF-1 by calculating PLR and NLR, which can be easier to relate to clinical practice than SROC and DOR. The pooled PLR value of 78.16 suggests that patients with metastatic pulmonary adenocarcinomas have an approximately 78-fold higher chance of giving a positive TTF-1 result than do patients without metastatic pulmonary adenocarcinomas. At the same time, the pooled NLR was 0.26, indicating that a negative TTF-1 result is still 26% likely to be a false negative, which is not low enough to rule out metastatic pulmonary adenocarcinomas.

The relatively low sensitivity of TTF-1 in identifying metastatic pulmonary adenocarcinoma cells in effusion samples means that it is probably not sufficiently reliable on its own. Instead it should be used in conjunction with other markers. For example, combining of TTF-1 and napsin A gave higher sensitivity and accuracy than TTF-1 alone in identifying metastatic pulmonary adenocarcinomas[@b34]. Carcino-embryonic antigen is often targeted during immunostaining of metastatic pulmonary adenocarcinoma in pleural or other effusions[@b41], so, including TTF-1 within a panel of immunostaining markers such as CEA, and napsin A, may increase the overall sensitivity and specificity, thereby improving overall accuracy.

Though TTF-1 may play a role in identifying malignant effusions, comparing the diagnostic performance of TTF-1 with that of classical tumor markers such as CA15-3 and vascular endothelial growth factor (VEGF) is difficult, because the two types of biomarker serve different purposes. Immunostaining for TTF-1 is done primarily to determine the source of malignant cells. When measured by ELISA on pleural fluid supernatants, TTF-1 had a poor diagnostic accuracy for differentiating malignant and benign effusions with the sensitivity of only 9%[@b10]. Examining markers such as CA 15-3 and VEGF, or using other diagnostic tools such as percutaneous pleural biopsy and VATS-directed biopsy, is done to determine whether effusions are malignant or benign[@b42][@b43][@b44][@b45].

TTF-1 is also a sensitive marker for papillary carcinoma of the thyroid, although it is estimated that fewer than 1% of patients with papillary thyroid carcinoma have malignant pleural effusions[@b46]. In this meta-analysis, only one case of thyroid carcinoma was reported in 545 patients with non-pulmonary adenocarcinomas. The rarity of metastatic thyroid carcinoma in serous effusions explains the nearly 100% specificity of TTF-1 in detecting metastatic lung adenocarcinoma across several studies.

Our meta-analysis results indicated an association between TTF-1 and presence of metastatic pulmonary adenocarcinomas, implying that TTF-1 may contribute to such metastasis. Winslow *et al.* reported that downregulation of TTF-1 is associated with loss of differentiation, enhanced tumor seeding ability and increased metastatic potential in lung adenocarcinoma[@b47]. Positive and partially positive TTF-1 expression in lung adenocarcinoma patients correlates with EGFR mutations (exon 19 and 21). In clinical practice, the combination of TTF-1 expression and EGFR mutations, especially mutations in exon 21, can guide timely clinical treatment for lung adenocarcinomas[@b48]. Future studies should examine how TTF-1 functions in lung adenocarcinoma-related regulatory and signaling pathways. At the same time, researchers and clinicians should not overextend their interpretations of TTF-1 expression, which should be taken into account only when malignant cells are present. Indeed, the requirement for malignant cells limits the diagnostic sensitivity and clinical significance of TTF-1, and distinguishes it from assays based on circulating tumor DNA or classical tumor markers.

Standardized techniques for detecting TTF-1 should be established in order to maximize the clinical utility of this biomarker. Studies should rigorously determine whether immunohistochemistry or immunocytochemistry is superior, and the dilution of primary antibody should be optimized. Dilution factors among the studies in this meta-analysis ranged from 1:40 to 1:500. Studies should also compare the different primary antibodies available; one study has suggested that the SPT24 antibody clone is better than the 8G7G3/1 clone[@b49]. It may also be possible to improve sensitivity or specificity of immunohistochemical staining by optimizing antibody cut-off values[@b50].

The findings of this meta-analysis should be interpreted with caution because of several limitations. While our strict inclusion and exclusion criteria may have helped reduce selection bias, they led to a relatively small final set of studies for which statistical power may be inadequate for drawing definitive conclusions about the ability of TTF-1 to discriminate metastatic pulmonary adenocarcinomas from metastatic non-pulmonary adenocarcinomas in pleural or other effusions. For example, we included only studies published in English and Chinese in a relatively small number of databases. Our results may be biased by our omission of unpublished studies, studies published in other languages and studies published in journals not indexed in the databases we searched. In addition, we detected substantial heterogeneity across the included studies, for which we were unable to identify causes using meta-regression. Future studies should aim for greater rigor in order to decrease the risk of bias.

Conclusions
===========

In summary, our meta-analysis suggests that TTF-1 may significantly aid the diagnosis of metastatic pulmonary adenocarcinomas in pleural or other effusions. Our data provide further evidence that TTF-1 is a useful marker for distinguishing metastatic adenocarcinoma of the lung from non-pulmonary adenocarcinoma in specimens of pleural or other effusions.
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![Summary of QUADAS-2 assessments of included studies.\
QUADAS-2: Quality Assessment of Diagnostic Accuracy Studies-2. Patient Selection: Describe methods of patient selection; Index Text: Describe the index test and how it was conducted and interpreted; Reference Standard: Describe the reference standard and how it was conducted and interpreted; Flow and Timing: Describe any patients who did not receive the index tests or reference standard or who were excluded from the 2 × 2 table, and describe the interval and any interventions between index tests and the reference standard. (From *Ann Intern Med.* 2011; 155(8):529--36.)](srep19785-f2){#f2}

![Forest plots of diagnostic odds ratio of thyroid transcription factor-1.\
The pooled diagnostic odds ratio was 297.75 (95% CI: 104.16--851.19).](srep19785-f3){#f3}

![Summary receiver operating characteristic (SROC) curves for the detection of metastatic pulmonary adenocarcinoma using thyroid transcription factor-1.\
The SROC curve with confidence and prediction regions around mean operating sensitivity and specificity point analyses of TTF-1. AUC, area under the curve; SENS, sensitivity; SPEC, specificity.](srep19785-f4){#f4}

![Fagan plot analysis to evaluate the clinical utility of thyroid transcription factor-1 for the detection of metastatic pulmonary adenocarcinoma.](srep19785-f5){#f5}

![Deeks's funnel plot to assess the likelihood of publication bias.\
The statistically non-significant P-value of 0.11 for the slope coefficient suggests symmetry in the data and a low likelihood of publication bias.](srep19785-f6){#f6}

###### Clinical summary of included studies.

  Author (Ref)               Year   Country   Subjects    Samples          Sample        TTF-1    TTF-1    Dilution              Cut-off
  ------------------------- ------ --------- ---------- ------------ ------------------ ------- --------- ---------- -------------------------------
  Hecht JL[@b15]             2001     USA        88      PE,PTE,PAE      Cell block       IHC    8G7G3/1    1:200           Nuclear staining
  Jiang KY[@b16]             2001    Korea       56        PE,PTE        Cell block       IHC    8G7G3/1      NA      Nuclear staining (≥10% cells)
  Afify AM[@b17]             2002     USA        70          SF          Cell block       IHC    8G7G3/1     1:40           Nuclear staining
  Gomez-Fernandez C[@b18]    2002     USA       113        PE,PTE        Cell block       ICC    8G7G3/1    1:150     Nuclear staining (≥10% cells)
  Ng WK[@b19]                2002    China       36      PE,PTE,PAE      Cell block       IHC    8G7G3/1     1:50           Nuclear staining
  Su X[@b20]                 2004    China       60      PE,PTE,PAE      Cell block       ICC    8G7G3/1     RTU            Nuclear staining
  Jan IS[@b21]               2006    China       75        PE,PAE          Smear          ICC    8G7G3/1    1:200     Nuclear staining (≥10% cells)
  Dejmek A[@b22]             2007   Sweden       32          PE          Cell block       IHC    8G7G3/1    1:100           Nuclear staining
  Zhou C[@b23]               2007    China       48          PE          Cell block       IHC    8G7G3/1    1:100           Nuclear staining
  Zhu W[@b24]                2007     USA        46          SF          Cell block       IHC    8G7G3/1    1:200           Nuclear staining
  Jiang B[@b25]              2008    China       48          PE          Cell block       ICC    8G7G3/1      NA      Nuclear staining (≥10% cells)
  Wang J[@b26]               2008    China       53          PE          Cell block       IHC    8G7G3/1      NA            Nuclear staining
  Kim JH[@b27]               2010    Korea       97        PE,PTE        Cell block       ICC    8G7G3/1     1:50           Nuclear staining
  Khoor A[@b28]              2011     USA        52          PE          Cell block       ICC    8G7G3/1    1:500           Nuclear staining
  Kim JH[@b29]               2011    Korea       84          PE          Cell block       IHC    8G7G3/1     1:50           Nuclear staining
  Liu L[@b30]                2012     USA        38          PE       Smear/Cell block    IHC     SPT24      RTU      Nuclear staining (≥10% cells)
  Liu Y[@b31]                2012    China       65      PE,PTE,PAE      Cell block       IHC     SPT24       NA      Nuclear staining (≥5% cells)
  Luo Q[@b32]                2012    China       31        PE,PTE        Cell block       ICC      NA         NA      Nuclear staining (≥10% cells)
  Yan J[@b33]                2014    China       76          PE          Cell block       ICC    8G7G3/1     1:50     Nuclear staining (≥5% cells)
  Yin J[@b34]                2014    China       45         PAE          Cell block       IHC     SPT24      RTU            Nuclear staining

ICC: Immunocytochemistry; IHC: Immunohistochemistry; NA: Not available; PAE: pericardial effusion; PE: Pleural effusion; PTE: peritoneal effusion; RTU: Ready to use; TTF-1: Thyroid transcription factor 1.

###### Diagnostic performance of thyroid transcription factor-1 and design from individual studies.

  Author (Ref)               Cases   Controls   TP   FP   FN   TN   Design   Blinded?
  ------------------------- ------- ---------- ---- ---- ---- ---- -------- ----------
  Hecht JL[@b15]              39        49      34   1    5    48     NA        NA
  Jiang KY[@b16]              16        40      13   0    3    40     R         NA
  Afify AM[@b17]              34        36      27   0    7    36     R         NA
  Gomez-Fernandez C[@b18]     39        74      21   0    18   74     R        Yes
  Ng WK[@b19]                 17        19      15   0    2    19     R         NA
  Su X[@b20]                  36        24      26   2    10   22     R         NA
  Jan IS[@b21]                50        25      41   0    9    25     R        Yes
  Dejmek A[@b22]              12        20      8    0    4    20     P        Yes
  Zhou C[@b23]                37        11      28   0    9    11     NA        NA
  Zhu W[@b24]                 13        33      9    0    4    33     R        Yes
  Jiang B[@b25]               43        5       30   0    13   5      P        Yes
  Wang J[@b26]                35        18      24   1    11   17     R         NA
  Kim JH[@b27]                52        45      30   0    22   45     P        Yes
  Khoor A[@b28]               26        26      19   0    7    26     R        Yes
  Kim JH[@b29]                53        31      30   0    23   31     R        Yes
  Liu L[@b30]                 23        15      20   0    3    15     R        Yes
  Liu Y[@b31]                 45        20      39   1    6    19     R        Yes
  Luo Q[@b32]                 15        16      11   0    4    16     R         NA
  Yan J[@b33]                 51        25      39   1    12   24     R         NA
  Yin J[@b34]                 32        13      24   0    8    13     R         NA

NA: Not available; P: Prospective; R: retrospective; FN: False negative; FP: False positive; TN: True negative; TP: True positive;

###### Mata-regression of potential heterogeneity within the included studies.

  Covariates               Number of studies   Coefficient     SE       RDOR(95%CI)      P value
  ----------------------- ------------------- ------------- -------- ------------------ ---------
  Country                                                                               
   Asian                          13             −0.654      0.7549   0.52(0.10--2.69)   0.4032
   non-Asian                       7                                                         
  TTF-1 assay method                                                                    
   IHC                            12              0.372      0.6542   1.45(0.35--6.04)    0.58
   ICC                             8                                                         
  TTF-1 clone                                                                           
   8G7G3/1                        16             −0.296      0.9242   0.74(0.10--5.57)   0.7543
   Other                           4                                                         
  TTF-1 dilution                                                                        
   ≤1:150                          8              0.216      0.7699   1.24(0.23--6.64)   0.7843
   1:150 and other                12                                                         
  Study Design                                                                          
   Prospective                     4             −0.617      1.0947   0.54(0.05--5.86)   0.5835
   Retrospective and NA           16                                                         
  Blinding                                                                              
   Yes                            10               0.1       0.7958   1.11(0.20--6.26)   0.9016
   No and NA                      10                                                         

ICC: Immunocytochemistry; IHC: Immunohistochemistry; NA: Not available; RDOR: Relative diagnostic odds ratio; SE: Standard error; TTF-1: Thyroid transcription factor 1;

[^1]: These authors contributed equally to this work.
